LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Stock List・United Therapeutics Corp

United Therapeutics Corp

Closed

SectorHealthcare

567.25 -0.12

Buy Sell

Overview

Share price change

24h

Current

Min

559.78

Max

569.82

Key metrics
By Trading Economics
Income	-89M 275M
Sales	-8.7M 782M
P/E Sector Avg	20.882 51.415
EPS	5.82
Profit margin	35.176
Employees	1,400
EBITDA	-176M 348M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+14.16% upside

Dividends
By Dow Jones
Next Earnings	29 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-476M 24B
Previous open	567.37
Previous close	567.25

News Sentiment

By Acuity

46%

54%

145 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

292.345 / 309.245 Support & Resistance

United Therapeutics Corp Chart

Past performance is not a reliable indicator of future results.

Related News

18 May 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Agilysys, XP

18 May 2026, 18:44 UTC

Major Market Movers

Claritev Shares Recover After Comments About DOJ

18 May 2026, 23:55 UTC

Earnings

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 May 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 May 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 May 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 May 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 May 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 May 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 May 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 May 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

18 May 2026, 20:25 UTC

Earnings

Correct: XP 1Q Total Client Assets BRL1.53T

18 May 2026, 20:23 UTC

Earnings

XP 1Q Total Client Assets BRL1.53B

18 May 2026, 20:19 UTC

Earnings

XP 1Q Adj EPS BRL2.49 >XP

18 May 2026, 20:19 UTC

Earnings

XP 1Q Rev BRL4.73B >XP

18 May 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 May 2026, 19:00 UTC

Earnings

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 May 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 May 2026, 18:17 UTC

Market Talk

Acquisitions, Mergers, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 May 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 May 2026, 16:57 UTC

Acquisitions, Mergers, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 May 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 May 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 May 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 May 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 May 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 May 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 May 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Vinci Buys Canada's Modern Group of Companies

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

14.16% upside

12 Months Forecast

Average 649.08 USD 14.16%

High 738 USD

Low 516 USD

Based on 13 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to United Therapeutics Corp - Dist in the past 3 months.

Technical Score

By Trading Central

292.345 / 309.245Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

145 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.